ALK and non-small cell lung carcinoma: For the 79 patients with ALK+ NSCLC, the KM-estimated median PFS was 14.5 months (95% CI: 10.8–21.2), with PFS rates of 21% (95% CI: 12–32) at 3 years and 12% (95% CI: 5–22) at 5 years (Fig. 2A; Table 1).